138 related articles for article (PubMed ID: 36195286)
1. A first-in-class clinical G-quadruplex-targeting drug. The bench-to-bedside translation of the fluoroquinolone QQ58 to CX-5461 (Pidnarulex).
Xu H; Hurley LH
Bioorg Med Chem Lett; 2022 Dec; 77():129016. PubMed ID: 36195286
[TBL] [Abstract][Full Text] [Related]
2. A synthetic lethal approach to drug targeting of G-quadruplexes based on CX-5461.
Jin M; Hurley LH; Xu H
Bioorg Med Chem Lett; 2023 Jul; 91():129384. PubMed ID: 37339720
[TBL] [Abstract][Full Text] [Related]
3. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination.
de Campos-Nebel M; Larripa I; González-Cid M
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824055
[TBL] [Abstract][Full Text] [Related]
4. Genetic evidence for involvement of two distinct nonhomologous end-joining pathways in repair of topoisomerase II-mediated DNA damage.
Adachi N; Iiizumi S; So S; Koyama H
Biochem Biophys Res Commun; 2004 Jun; 318(4):856-61. PubMed ID: 15147950
[TBL] [Abstract][Full Text] [Related]
5. CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours.
Xu H; Di Antonio M; McKinney S; Mathew V; Ho B; O'Neil NJ; Santos ND; Silvester J; Wei V; Garcia J; Kabeer F; Lai D; Soriano P; Banáth J; Chiu DS; Yap D; Le DD; Ye FB; Zhang A; Thu K; Soong J; Lin SC; Tsai AH; Osako T; Algara T; Saunders DN; Wong J; Xian J; Bally MB; Brenton JD; Brown GW; Shah SP; Cescon D; Mak TW; Caldas C; Stirling PC; Hieter P; Balasubramanian S; Aparicio S
Nat Commun; 2017 Feb; 8():14432. PubMed ID: 28211448
[TBL] [Abstract][Full Text] [Related]
6. Roles of nonhomologous end-joining pathways in surviving topoisomerase II-mediated DNA damage.
Malik M; Nitiss KC; Enriquez-Rios V; Nitiss JL
Mol Cancer Ther; 2006 Jun; 5(6):1405-14. PubMed ID: 16818498
[TBL] [Abstract][Full Text] [Related]
7. Transcription-associated topoisomerase 2α (TOP2A) activity is a major effector of cytotoxicity induced by G-quadruplex ligands.
Bossaert M; Pipier A; Riou JF; Noirot C; Nguyên LT; Serre RF; Bouchez O; Defrancq E; Calsou P; Britton S; Gomez D
Elife; 2021 Jun; 10():. PubMed ID: 34180392
[TBL] [Abstract][Full Text] [Related]
8. Type II DNA Topoisomerases Cause Spontaneous Double-Strand Breaks in Genomic DNA.
Morimoto S; Tsuda M; Bunch H; Sasanuma H; Austin C; Takeda S
Genes (Basel); 2019 Oct; 10(11):. PubMed ID: 31671674
[TBL] [Abstract][Full Text] [Related]
9. Molecular Dynamics Study on the Binding of an Anticancer DNA G-Quadruplex Stabilizer, CX-5461, to Human Telomeric, c-KIT1, and c-Myc G-Quadruplexes and a DNA Duplex.
Sullivan HJ; Chen B; Wu C
J Chem Inf Model; 2020 Oct; 60(10):5203-5224. PubMed ID: 32820923
[TBL] [Abstract][Full Text] [Related]
10. Differential and common DNA repair pathways for topoisomerase I- and II-targeted drugs in a genetic DT40 repair cell screen panel.
Maede Y; Shimizu H; Fukushima T; Kogame T; Nakamura T; Miki T; Takeda S; Pommier Y; Murai J
Mol Cancer Ther; 2014 Jan; 13(1):214-20. PubMed ID: 24130054
[TBL] [Abstract][Full Text] [Related]
11. Anti-tumoural activity of the G-quadruplex ligand pyridostatin against BRCA1/2-deficient tumours.
Groelly FJ; Porru M; Zimmer J; Benainous H; De Visser Y; Kosova AA; Di Vito S; Serra V; Ryan A; Leonetti C; Bruna A; Biroccio A; Tarsounas M
EMBO Mol Med; 2022 Mar; 14(3):e14501. PubMed ID: 35107878
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 ensures genome integrity by eliminating estrogen-induced pathological topoisomerase II-DNA complexes.
Sasanuma H; Tsuda M; Morimoto S; Saha LK; Rahman MM; Kiyooka Y; Fujiike H; Cherniack AD; Itou J; Callen Moreu E; Toi M; Nakada S; Tanaka H; Tsutsui K; Yamada S; Nussenzweig A; Takeda S
Proc Natl Acad Sci U S A; 2018 Nov; 115(45):E10642-E10651. PubMed ID: 30352856
[TBL] [Abstract][Full Text] [Related]
13. Dual functions of the homeoprotein DLX4 in modulating responsiveness of tumor cells to topoisomerase II-targeting drugs.
Trinh BQ; Ko SY; Barengo N; Lin SY; Naora H
Cancer Res; 2013 Jan; 73(2):1000-10. PubMed ID: 23222298
[TBL] [Abstract][Full Text] [Related]
14. TDP2-dependent non-homologous end-joining protects against topoisomerase II-induced DNA breaks and genome instability in cells and in vivo.
Gómez-Herreros F; Romero-Granados R; Zeng Z; Alvarez-Quilón A; Quintero C; Ju L; Umans L; Vermeire L; Huylebroeck D; Caldecott KW; Cortés-Ledesma F
PLoS Genet; 2013; 9(3):e1003226. PubMed ID: 23505375
[TBL] [Abstract][Full Text] [Related]
15. Ubiquitin-mediated DNA damage response is synthetic lethal with G-quadruplex stabilizer CX-5461.
Masud T; Soong C; Xu H; Biele J; Bjornson S; McKinney S; Aparicio S
Sci Rep; 2021 May; 11(1):9812. PubMed ID: 33963218
[TBL] [Abstract][Full Text] [Related]
16. G-quadruplex DNA as a molecular target for induced synthetic lethality in cancer cells.
McLuckie KI; Di Antonio M; Zecchini H; Xian J; Caldas C; Krippendorff BF; Tannahill D; Lowe C; Balasubramanian S
J Am Chem Soc; 2013 Jul; 135(26):9640-3. PubMed ID: 23782415
[TBL] [Abstract][Full Text] [Related]
17. Design, synthesis, and biological evaluation of a series of fluoroquinoanthroxazines with contrasting dual mechanisms of action against topoisomerase II and G-quadruplexes.
Kim MY; Duan W; Gleason-Guzman M; Hurley LH
J Med Chem; 2003 Feb; 46(4):571-83. PubMed ID: 12570378
[TBL] [Abstract][Full Text] [Related]
18. Hypersensitivity of nonhomologous DNA end-joining mutants to VP-16 and ICRF-193: implications for the repair of topoisomerase II-mediated DNA damage.
Adachi N; Suzuki H; Iiizumi S; Koyama H
J Biol Chem; 2003 Sep; 278(38):35897-902. PubMed ID: 12842886
[TBL] [Abstract][Full Text] [Related]
19. Tyrosyl-DNA phosphodiesterase (Tdp1) participates in the repair of Top2-mediated DNA damage.
Nitiss KC; Malik M; He X; White SW; Nitiss JL
Proc Natl Acad Sci U S A; 2006 Jun; 103(24):8953-8. PubMed ID: 16751265
[TBL] [Abstract][Full Text] [Related]
20. DNA-PKcs-dependent NHEJ pathway supports the progression of topoisomerase II poison-induced chromosome aberrant cells.
Elguero ME; de Campos-Nebel M; González-Cid M
Environ Mol Mutagen; 2012 Oct; 53(8):608-18. PubMed ID: 22987276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]